| 2.87 0.1 (3.61%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.45 | 1-year : | 4.03 |
| Resists | First : | 2.96 | Second : | 3.45 |
| Pivot price | 2.65  |
|||
| Supports | First : | 2.55 | Second : | 2.29 |
| MAs | MA(5) : | 2.77 |
MA(20) : | 2.64 |
| MA(100) : | 2.92  |
MA(250) : | 3.6 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 73.9 |
D(3) : | 71.5 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 8.53 | Low : | 2.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GNLX ] has closed below upper band by 8.0%. Bollinger Bands are 41.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 70 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.95 - 2.96 | 2.96 - 2.98 |
| Low: | 2.71 - 2.72 | 2.72 - 2.73 |
| Close: | 2.85 - 2.87 | 2.87 - 2.89 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Wed, 06 May 2026
GNLX SEC Filings - Genelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 01 May 2026
Genelux Corp expected to post a loss of 18 cents a share - Earnings Preview - TradingView
Wed, 29 Apr 2026
Genelux (NASDAQ: GNLX) details 2026 virtual meeting, board and auditor votes - Stock Titan
Thu, 26 Mar 2026
Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com
Thu, 19 Mar 2026
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewswire
Sat, 07 Mar 2026
Genelux Corp. (GNLX) Gets a Buy from Maxim Group - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 3.615e+007 (%) |
| Held by Institutions | 10.7 (%) |
| Shares Short | 2,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.297e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -117 % |
| Return on Assets (ttm) | 650 % |
| Return on Equity (ttm) | -77.3 % |
| Qtrly Rev. Growth | 8000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -369.57 |
| EBITDA (p.s.) | 17391.3 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 4.25 |
| Dividend | 0 |
| Forward Dividend | 3.02e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|